LLY

1,148

-0.09%↓

JNJ

239.84

+3.29%↑

ABBV

226.5

+1.02%↑

UNH

408.77

-0.08%↓

MRK

118.48

-0.66%↓

LLY

1,148

-0.09%↓

JNJ

239.84

+3.29%↑

ABBV

226.5

+1.02%↑

UNH

408.77

-0.08%↓

MRK

118.48

-0.66%↓

LLY

1,148

-0.09%↓

JNJ

239.84

+3.29%↑

ABBV

226.5

+1.02%↑

UNH

408.77

-0.08%↓

MRK

118.48

-0.66%↓

LLY

1,148

-0.09%↓

JNJ

239.84

+3.29%↑

ABBV

226.5

+1.02%↑

UNH

408.77

-0.08%↓

MRK

118.48

-0.66%↓

LLY

1,148

-0.09%↓

JNJ

239.84

+3.29%↑

ABBV

226.5

+1.02%↑

UNH

408.77

-0.08%↓

MRK

118.48

-0.66%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

8.81 1.85

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.58

Max

8.99

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
EPS	-0.828
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+219.07% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-84M 760M
Vorige openingsprijs	6.96
Vorige sluitingsprijs	8.81

Nieuwssentiment

By Acuity

100%

315 / 344 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jun 2026, 23:49 UTC

Marktinformatie

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 jun 2026, 23:45 UTC

Acquisities, Fusies, Overnames

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 jun 2026, 23:44 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 jun 2026, 23:44 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 jun 2026, 23:43 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 jun 2026, 23:35 UTC

Marktinformatie

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 jun 2026, 22:06 UTC

Acquisities, Fusies, Overnames

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 jun 2026, 20:51 UTC

Winsten

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jun 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jun 2026, 20:09 UTC

Marktinformatie

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 jun 2026, 19:36 UTC

Marktinformatie

Cattle Climbs as Crude Oil Falls -- Market Talk

9 jun 2026, 19:32 UTC

Marktinformatie

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 jun 2026, 19:25 UTC

Marktinformatie

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 jun 2026, 19:00 UTC

Marktinformatie

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 jun 2026, 18:52 UTC

Acquisities, Fusies, Overnames

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 jun 2026, 18:47 UTC

Marktinformatie

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 jun 2026, 18:37 UTC

Marktinformatie

Canada's Cooling Trade With the U.S. -- Market Talk

9 jun 2026, 18:27 UTC

Marktinformatie

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 jun 2026, 17:35 UTC

Marktinformatie

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 jun 2026, 17:30 UTC

Marktinformatie

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 jun 2026, 16:34 UTC

Marktinformatie

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jun 2026, 15:28 UTC

Marktinformatie

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 jun 2026, 15:25 UTC

Marktinformatie

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

219.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 219.07%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

315 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.